

ENZOLYTICS, INC.

1101 Raintree Circle, Suite 130, Allen, Texas 75013

972-292-9414

www.enzolytics.com

info@enzolytics.com

Annual Report

For the period ending December 31, 2023 (the "Reporting Period")

Outstanding Shares

The number of shares outstanding of our Common Stock was:

3,187,974,957 as of December 31, 2023

3,187,974,957 as of December 31, 2023

Shell Status

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933, Rule 12b-2 of the Exchange Act of 1934 and Rule 15c2-11 of the Exchange Act of 1934):

Yes: ☐ No: ☒

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: ☐ No: ☒

Change in Control

Indicate by check mark whether a Change in Control⁴ of the company has occurred during this reporting period:

Yes: ☒ No: ☐

⁴ "Change in Control" shall mean any events resulting in:

- (i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;
- (ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;
- (iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or
- (iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

1) Name and address(es) of the issuer and its predecessors (if any)

In answering this item, provide the current name of the issuer and names used by predecessor entities, along with the dates of the name changes.

| | |
|---|--------------------|
| Enzolytics, Inc. | |
| Immunotech Laboratories, Inc. | September 11, 2017 |
| Eco-Petroleum Solutions, Inc. | November 16, 2012 |
| Structural Enhancement Technologies Corp. | May 10, 2010 |
| Extreme Mobile Coatings Worldwide Corp. | May 2, 2009 |
| Extreme Mobile Coatings Corp. Ltd. | October 10, 2008 |
| Falcon Media Services, Ltd. | November 24, 200 |
| 4T&T Homes Limited | July 28, 2004 |

Current State and Date of Incorporation or Registration: Delaware, November 4, 2020

Standing in this jurisdiction: (e.g. active, default, inactive): active

Prior Incorporation Information for the issuer and any predecessors during the past five years:

Wyoming May 2q, 2020

Describe any trading suspension or halt orders issued by the SEC or FINRA concerning the issuer or its predecessors since inception:

None

List any stock split, dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

The Company is anticipating a spin-off of its wholly owned subsidiary Robustomed, Inc. as a result of the reorganization effected by a merger conducted pursuant to Section 251(g) of the Delaware General Corporation Law (the "DGCL")

Address of the issuer's principal executive office:

1101 Raintree Circle, Suite 130
Allen, Texas 75013

Address of the issuer's principal place of business:

x Check if principal executive office and principal place of business are the same address:

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

No: ☒ Yes: ☐ If Yes, provide additional details below:

2) Security Information

OTC Pink Basic Disclosure Guidelines (v4.0 January 1, 2023)

Transfer Agent

Name: Empire Stock Transfer
Phone: 702-818-5898
Email: info@empirestock.com
Address: 1859 Whitney Mesa Dr.
Henderson, NV 89+014

Publicly Quoted or Traded Securities:

The goal of this section is to provide a clear understanding of the share information for its publicly quoted or traded equity securities. Use the fields below to provide the information, as applicable, for all outstanding classes of securities that are publicly traded/quoted.

| | |
|--|--------------------------------------|
| Trading symbol: | ENZC PK |
| Exact title and class of securities outstanding: | COMMON |
| CUSIP: | 294112107 |
| Par or stated value: | 0.0001 |
| Total shares authorized: | 3,750,000,000 as of date: 12/31/2023 |
| Total shares outstanding: | 3,172,974,957 as of date: 12/31/2023 |
| Total number of shareholders of record: | 244 as of date: 12/31/2023 |

Please provide the above-referenced information for all other publicly quoted or traded securities of the issuer.

Other classes of authorized or outstanding equity securities that do not have a trading symbol:

The goal of this section is to provide a clear understanding of the share information for its other classes of authorized or outstanding equity securities (e.g., preferred shares that do not have a trading symbol). Use the fields below to provide the information, as applicable, for all other authorized or outstanding equity securities.

| | |
|---|-----------------------------------|
| Exact title and class of the security: | Series A Preferred |
| Par or stated value: | 0.0001 |
| Total shares authorized: | 60,000,000 as of date: 12/31/2023 |
| Total shares outstanding: | 13,200,000 as of date: 12/31/2023 |
| Total number of shareholders of record: | 2 as of date: 12/31/2023 |

| | |
|---|------------------------------------|
| Exact title and class of the security: | Series B Preferred |
| Par or stated value: | 0.0001 |
| Total shares authorized: | 465,000,000 as of date: 12/31/2023 |
| Total shares outstanding: | 442,880,000 as of date: 12/31/2023 |
| Total number of shareholders of record: | 10 as of date: 12/31/2023 |

OTC Pink Basic Disclosure Guidelines (v4.0 January 1, 2023)

| | | |
|---|--------------------|------------------------|
| Exact title and class of the security: | Series C Preferred | |
| Par or stated value: | 0.0001 | |
| Total shares authorized: | 10,000,000 | as of date: 12/31/2023 |
| Total shares outstanding: | 3,452,907 | as of date: 12/31/2023 |
| Total number of shareholders of record: | 5 | as of date: 12/31/2023 |

| | | |
|---|--------------------|------------------------|
| Exact title and class of the security: | Series D Preferred | |
| Par or stated value: | 0.0001 | |
| Total shares authorized: | 1,000,000 | as of date: 12/31/2023 |
| Total shares outstanding: | 0 | as of date: 12/31/2023 |
| Total number of shareholders of record: | 0 | as of date: 12/31/2023 |

| | | |
|---|--------------------|------------------------|
| Exact title and class of the security: | Series E Preferred | |
| Par or stated value: | 0.0001 | |
| Total shares authorized: | 10,000,000 | as of date: 12/31/2023 |
| Total shares outstanding: | 0 | as of date: 12/31/2023 |
| Total number of shareholders of record: | 0 | as of date: 12/31/2023 |

| | | |
|---|--------------------|------------------------|
| Exact title and class of the security: | Series F Preferred | |
| Par or stated value: | 0.0001 | |
| Total shares authorized: | 10,000,000 | as of date: 12/31/2023 |
| Total shares outstanding: | 0 | as of date: 12/31/2023 |
| Total number of shareholders of record: | 0 | as of date: 12/31/2023 |

Please provide the above-referenced information for all other classes of authorized or outstanding equity securities.

Security Description:

The goal of this section is to provide a clear understanding of the material rights and privileges of the securities issued by the company. Please provide the below information for each class of the company's equity securities, as applicable:

1. For common equity, describe any dividend, voting and preemption rights.

There is no dividend, or preemption rights with common equity. The voting rights are one vote for each share held.

2. For preferred stock, describe the dividend, voting, conversion, and liquidation rights as well as redemption or sinking fund provisions.

SERIES A PREFERRED

Designation and Rank. The Series A Preferred Stock shall rank: (i) senior to any other class or series of outstanding preferred shares or series of capital stock of the Company; (ii) prior to all of the Company's common stock, no par value per share; (iii) prior to any class or series of capital stock of the Company hereafter created not specifically ranking by its terms senior to or on parity with any Series A Preferred Stock of whatever subdivision (collectively, with the common stock and the existing preferred stock, "Junior Securities"); and (iv) on parity with any class or series of capital stock of the Company hereafter created specifically ranking by its terms on parity with the Series A Preferred Stock ("Parity Securities") in each case as to distributions of assets upon liquidation, dissolution or winding up of the Company, whether voluntary or involuntary (all such distributions being referred to collectively as "Distributions").

Dividends. The holders of the Series A Preferred Stock are not entitled to receive dividends.

Super Majority Voting Rights. The record holders of the Series A Preferred Shares shall have the right to vote on any matter with holders of common stock voting together as one (1) class. The record holders of the Series A Preferred Shares shall have that number of votes (identical in every other respect to the voting rights of the holders of other series of voting preferred shares and the holders of common stock entitled to vote at any regular or special meeting of the shareholders) equal to that number of common shares which is not less than 51% of the vote required to approve any action, which Delaware law provides may or must be approved by vote or consent of the holders of other series of voting preferred shares and the holders of common shares or the holders of other

securities entitled to vote, if any. For purposes of determining the number of votes, each one (1) share of the Series A Preferred shall have voting rights equal to (x) 0.019607 multiplied by the total issued and outstanding common stock eligible to vote at the time of the respective vote (the "Numerator"), divided by (y) 0.49, minus (z) the Numerator.

Redemption Rights. There are no redemption rights.

Liquidation Preference. In the event of any liquidation, dissolution or winding up of the Company, either voluntary or involuntary, the holders of shares of Series A Preferred Stock shall be entitled to receive, immediately after any distributions to senior securities required by the Company's Certificate of Incorporation or any certificate of designation, and prior in preference to any distribution to Junior Securities but in parity with any distribution to Parity Securities, an amount per share equal to \$.01 per share. If upon the occurrence of such event, and after payment in full of the preferential amounts with respect to the Senior Securities, the assets and funds available to be distributed among the holders of the Series A Preferred Stock and Parity Securities shall be insufficient to permit the payment to such holders of the full preferential amounts due to the holders of the Series A Preferred Stock and the Parity Securities, respectively, then the entire assets and funds of the Company legally available for distribution shall be distributed among the holders of the Series A Preferred Stock and the Parity Securities, pro rata, based on the respective liquidation amounts to which each such series of stock is entitled by the Company's Certificate of Incorporation and any certificate(s) of designation relating thereto.

SERIES B PREFERRED

Designation and Rank. The Series B Preferred Stock shall be subordinate to and rank junior to all indebtedness of the Company as well as the Series A Preferred Stock to the extent provided in the Certificate of Designation for the Series A Preferred Stock with the Series B Preferred Stock on the same footing as the Common Stock and Series A Preferred Stock.

Dividends. The holders of the Series B Preferred Stock are not entitled to receive dividends.

Voting Rights. The holders of Series B Preferred Stock shall have the right to cast 10 votes for each share held of record on all matters submitted to a vote of holders of the Corporation's common stock, including the election of directors, and all other matters as required by law. There is no right to cumulative voting in the election of directors. The holders of Series B Preferred Stock shall vote together with all other classes and series of common stock of the Company as a single class on all actions to be taken by the common stockholders of the Company except to the extent that voting as a separate class or series is required by law.

Liquidation Preference. In the event of any dissolution, liquidation or winding up of the Company whether voluntary or involuntary, the holders of Series B Preferred Stock shall be entitled to participate in any distribution out of the assets of the Company on an equal basis per share with the holders of the Common Stock and Series A Preferred Stock.

Conversion Rights. The holders of Series B Preferred Stock shall have conversion rights as follows: Each share of Series B Preferred

Stock shall be convertible at the option of the holder thereof and without the payment of additional consideration by the holder thereof, at any time, into shares of Common Stock in accordance with the stock designations filed with the office of the Delaware Secretary of State

SERIES C PREFERRED

Dividends. In each calendar year, the holders of the then outstanding shares of Series C Convertible Preferred Stock shall be entitled to receive, when, as and if declared by the Board, out of any funds and assets of the Company legally available therefore, noncumulative dividends in an amount equal to any dividends or other distribution on the Common Stock in such calendar year on an as-converted to-Common- Stock basis. No dividends shall be paid, and no Distribution shall be made, with respect to the Common Stock unless dividends in such amount shall have been paid or declared and set apart for payment to the holders of the Series C Convertible Preferred Stock simultaneously. Dividends on the Series C Convertible Preferred Stock shall not be mandatory or cumulative, and no rights or interest shall accrue to the holders of the Series C Convertible Preferred Stock.

Conversion Rights. Each share of Series C Convertible Preferred Stock shall be convertible, at the option of the holder thereof, at any time after the issuance of such shares, in accordance with the stock designations filed with the office of the Delaware Secretary of State. Notwithstanding the foregoing, in no event shall any holder of shares of Series C Convertible Preferred Stock be entitled to convert any shares of Series C Convertible Preferred Stock, and the Corporation shall not affect any conversion of the Series C Convertible Preferred Stock, to the extent that the number of shares of Common Stock issuable upon the conversion would result in beneficial ownership by the holder, its affiliates and any persons acting as a group together with such holder or its affiliates of more than 4.99% of the outstanding shares of Common Stock immediately after giving effect to the issuance of shares of Common Stock issuable upon conversion of the Series C Convertible Preferred Stock held by the applicable holder.

Redemption Rights. There are no redemption rights.

Voting Rights: Each share of Series C Convertible Preferred Stock shall be entitled to 100 votes on all matters to come before the Common Stock stockholders.

SERIES D PREFERRED

Dividends. In each calendar year, the holders of the then outstanding shares of Series D Convertible Preferred Stock shall be entitled to receive, when, as and if declared by the Board, out of any funds and assets of the Company legally available therefore, noncumulative dividends in an amount equal to any dividends or other distribution on the Common Stock in such calendar year on an as-converted to-Common- Stock basis. No dividends shall be paid, and no Distribution shall be made, with respect to the Common Stock unless dividends in such amount shall have been paid or declared and set apart for payment to the holders of the Series D Convertible Preferred Stock simultaneously. Dividends on the Series D Convertible Preferred Stock shall not be mandatory or cumulative, and no rights or interest shall accrue to the holders of the Series D Convertible Preferred Stock.

Conversion Rights. Each share of Series D Convertible Preferred Stock shall be convertible, at the option of the holder thereof, at any time after the issuance of such shares, in accordance with the stock designations filed with the office of the Delaware Secretary of State. Notwithstanding the foregoing, in no event shall any holder of shares of Series D Convertible Preferred Stock be entitled to convert any shares of Series D Convertible Preferred Stock, and the Corporation shall not affect any conversion of the Series D Convertible Preferred Stock, to the extent that the number of shares of Common Stock issuable upon the conversion would result in beneficial ownership by the holder, its affiliates and any persons acting as a group together with such holder or its affiliates of more than 4.99% of the outstanding shares of Common Stock immediately after giving effect to the issuance of shares of Common Stock issuable upon conversion of the Series D Convertible Preferred Stock held by the applicable holder.

Redemption Rights. There are no redemption rights.

Voting Rights: Each share of Series D Convertible Preferred Stock shall be entitled to 100 votes on all matters to come before the Common Stock stockholders.

SERIES E PREFERRED

Dividends. The holders of the Series E Preferred Stock are not entitled to receive dividends.

Voting Rights. The holders of Series E Preferred Stock shall have the right to cast 10 votes for each share held of record on all matters submitted to a vote of holders of the Corporation's common stock, including the election of directors, and all other matters as required by law. There is no right to cumulative voting in the election of directors. The holders of Series E Preferred Stock shall vote together with all other classes and series of common stock of the Company as a single class on all actions to be taken by the common stockholders of the Company except to the extent that voting as a separate class or series is required by law.

Liquidation Preference. In the event of any dissolution, liquidation or winding up of the Company whether voluntary or involuntary, the holders of Series E Preferred Stock shall be entitled to participate in any distribution out of the assets of the Company on an equal basis per share with the holders of the Common Stock and Series A, Series B and Series C Preferred Stock.

Conversion Rights. The holders of Series E Preferred Stock shall have conversion rights as follows: Each share of Series E Preferred Stock shall be convertible at the option of the holder thereof and without the payment of additional consideration by the holder thereof, at any time, into shares of Common Stock in accordance with the stock designations filed with the office of the Delaware Secretary of State

SERIES F PREFERRED (Subscribed but not issued by end of filing period)

Dividends. The holders of the Series F Preferred Stock are not entitled to receive dividends.

Voting Rights. The holders of Series F Preferred Stock shall have the right to cast 10 votes for each share held of record on all matters submitted to a vote of holders of the Corporation's common stock, including the election of

directors, and all other matters as required by law. There is no right to cumulative voting in the election of directors. The holders of Series E Preferred Stock shall vote together with all other classes and series of common stock of the Company as a single class on all actions to be taken by the common stockholders of the Company except to the extent that voting as a separate class or series is required by law.

Liquidation Preference. In the event of any dissolution, liquidation or winding up of the Company whether voluntary or involuntary, the holders of Series F Preferred Stock shall be entitled to participate in any distribution out of the assets of the Company on an equal basis per share with the holders of the Common Stock and Series A, Series B and Series C Preferred Stock.

Conversion Rights. The holders of Series F Preferred Stock shall have conversion rights as follows: Each share of Series F Preferred Stock shall be convertible at the option of the holder thereof and without the payment of additional consideration by the holder thereof, at any time, into shares of Common Stock in accordance with the stock designations filed with the office of the Delaware Secretary of State.

3. Describe any other material rights of common or preferred stockholders.

None.

4. Describe any material modifications to rights of holders of the company's securities that have occurred over the reporting period covered by this report.

None

3) Issuance History

*The goal of this section is to provide disclosure with respect to each event that resulted in any changes to the total shares outstanding of any class of the issuer's securities **in the past two completed fiscal years and any subsequent interim period.***

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

A. Changes to the Number of Outstanding Shares for the two most recently completed fiscal years and any subsequent period.

Indicate by check mark whether there were any changes to the number of outstanding shares within the past two completed fiscal years:

No: ☐ Yes: ☒ (If yes, you must complete the table below)

OTC Markets Group Inc.

| Shares Outstanding as of Second Most Recent Fiscal Year End: Opening Balance Date <u>12/31/2021</u> Common: <u>2,797,935,953</u> Preferred A: <u>60,000,000</u> Preferred B: <u>445,180,000</u> Preferred C: <u>941,078</u> Preferred D: <u>0</u> Preferred E: <u>2,500,000</u> | | | *Right-click the rows below and select "Insert" to add rows as needed. | | | | | | |
|--|---|--|--|---|--|--|---|---|---------------------------------|
| Date of Transaction | Transaction type (e.g. new issuance, cancellation shares returned to treasury) | Number of Shares Issued (or cancelled) | Class of Securities | Value of Shares Issued (\$/per share) at Issuance | Were the shares issued at a discount to market price at the time of issuance? (Yes/No) | Individual/ Entity Shares were issued to (entities must have individual with voting / investment control disclosed). | Reason for share issuance (e.g. for cash or debt conversion) -OR- Nature of Services Provided | Restricted or Unrestricted as of this filing. | Exemption or Registration Type. |
| <u>May 9, 2022</u> | <u>Issuance</u> | <u>21,259</u> | <u>Series D</u> | .0001 | <u>no</u> | Crowdfunding Conversion | <u>Debt exchange</u> | <u>Restricted</u> | <u>Registration</u> |
| <u>May 19, 2022</u> | <u>Issuance</u> | <u>2,500,000</u> | <u>Series E</u> | .001 | <u>no</u> | Valentin Dimitrov | <u>Cash</u> | <u>Restricted</u> | <u>Registration</u> |
| <u>March 31, 2023</u> | <u>Issuance</u> | <u>25,000,000</u> | <u>Common</u> | .001 | <u>no</u> | Mt. Roe Corporation V. | <u>Conversion of Series E</u> | <u>Restricted</u> | <u>Registration</u> |

| | | | | | | | | | |
|-----------------------|-------------------|--------------------|-----------------|-------------|-----------|--------------------------------------|-------------------------------|--------------------------|---------------------|
| <u>March 31, 2023</u> | <u>Issuance</u> | <u>25,000,000</u> | <u>Common</u> | <u>.001</u> | <u>no</u> | Mt. Roe Corporation V. Dimitrov | <u>Conversion of Series E</u> | <u>Restricted</u> | <u>Registration</u> |
| <u>March 31, 2023</u> | <u>Issuance</u> | <u>(2,500,000)</u> | <u>Common</u> | <u>.001</u> | <u>no</u> | Mt. Roe Corporation V. Dimitrov | <u>Conversion of Series E</u> | <u>Restricted</u> | <u>Registration</u> |
| <u>March 31, 2023</u> | <u>Issuance</u> | <u>(2,500,000)</u> | <u>Common</u> | <u>.001</u> | <u>no</u> | Mt. Roe Corporation V. Dimitrov | <u>Conversion of Series E</u> | <u>Restricted</u> | <u>Registration</u> |
| <u>April 19, 2023</u> | <u>Issuance</u> | <u>10,000,000</u> | <u>Common</u> | <u>.001</u> | <u>no</u> | Kelli Austin | <u>Consulting Contract</u> | <u>Restricted</u> | <u>Registration</u> |
| <u>May 12, 2023</u> | <u>Conversion</u> | <u>(2,000,000)</u> | <u>Series B</u> | <u>.001</u> | <u>no</u> | Harry Zhabilov | <u>Conversion of Series B</u> | <u>Restricted</u> | <u>Registration</u> |
| <u>May 12, 2023</u> | <u>Conversion</u> | <u>20,000,000</u> | <u>Common</u> | <u>.001</u> | <u>no</u> | Harry Zhabiov | <u>Conversion of Series B</u> | <u>Unrestricted</u> – | <u>Registration</u> |
| <u>May 22, 2023</u> | <u>Conversion</u> | <u>8,218,700</u> | <u>Common</u> | <u>.001</u> | <u>no</u> | Sky_Direct Steve Apolant | <u>Conversion of Series C</u> | <u>Unrestricted</u> – | <u>Registration</u> |
| <u>May 22, 2023</u> | <u>Conversion</u> | <u>(82,187)</u> | <u>Series C</u> | <u>.001</u> | <u>no</u> | Sky_Direct Steve Apolant | <u>Conversion of Series C</u> | <u>Unrestricted</u> – | <u>Registration</u> |
| <u>May 22, 2023</u> | <u>Conversion</u> | <u>554,900</u> | <u>Common</u> | <u>.001</u> | <u>no</u> | Sky_Direct Steve Apolant | <u>Conversion of Series C</u> | <u>Unrestricted</u> – | <u>Registration</u> |
| <u>May 22, 2023</u> | <u>Conversion</u> | <u>(5,549)</u> | <u>Series C</u> | <u>.001</u> | <u>no</u> | Sky_Direct Steve Apolant | <u>Conversion of Series C</u> | <u>Unrestricted</u> – | <u>Registration</u> |
| <u>May 22, 2023</u> | <u>Conversion</u> | <u>2,692,700</u> | <u>Common</u> | <u>.001</u> | <u>no</u> | Sky_Direct Steve Apolant | <u>Conversion of Series C</u> | <u>Unrestricted</u> – | <u>Registration</u> |
| <u>May 22, 2023</u> | <u>Conversion</u> | <u>(26,927)</u> | <u>Series C</u> | <u>.001</u> | <u>no</u> | Sky_Direct Steve Apolant | <u>Conversion of Series C</u> | <u>Unrestricted</u> – | <u>Registration</u> |
| <u>May 22, 2023</u> | <u>Conversion</u> | <u>28,350,000</u> | <u>Common</u> | <u>.001</u> | <u>no</u> | Sky_Direct Steve Apolant | <u>Conversion of Series C</u> | <u>Unrestricted</u> – | <u>Registration</u> |
| <u>May 22, 2023</u> | <u>Conversion</u> | <u>(283,508))</u> | <u>Series C</u> | <u>.001</u> | <u>no</u> | Sky_Direct Steve Apolant | <u>Conversion of Series C</u> | <u>Unrestricte</u> – | <u>Registration</u> |
| <u>May 25, 2023</u> | <u>Issuance</u> | <u>450,000</u> | <u>Series C</u> | <u>.001</u> | <u>no</u> | Sky_Direct Steve Apolant | <u>Subscription Agreement</u> | <u>Restricted</u> | <u>Registration</u> |
| <u>May 25, 2023</u> | <u>Issuance</u> | <u>350,000</u> | <u>Series C</u> | <u>.001</u> | <u>no</u> | NYFGroup Steve Apolant | <u>Subscription Agreement</u> | <u>Restricted</u> | <u>Registration</u> |
| <u>May 25, 2023</u> | <u>Issuance</u> | <u>550,000</u> | <u>Series C</u> | <u>.001</u> | <u>no</u> | Equity Market Advisors Steve Apolant | <u>Subscription Agreement</u> | <u>Restricted</u> | <u>Registration</u> |
| <u>May 25, 2023</u> | <u>Issuance</u> | <u>1,160,000</u> | <u>Series C</u> | <u>.001</u> | <u>no</u> | Seacor Lisa Ficarra | <u>Subscription Agreement</u> | <u>Restricted</u> | <u>Registration</u> |

| | | | | | | | | | |
|-------------------------|-------------------|--------------------|-----------------|-------|-----------|--------------------------------------|-------------------------------|-------------------|---------------------|
| <u>May 25, 2023</u> | <u>Issuance</u> | <u>200,000</u> | <u>Series C</u> | .001 | <u>no</u> | Kenny Orr | <u>Subscription Agreement</u> | <u>Restricted</u> | <u>Registration</u> |
| <u>May, 25, 2023</u> | <u>Issuance</u> | <u>400,000 ***</u> | <u>Series C</u> | .001 | <u>no</u> | Charles Cotropia | <u>Subscription Agreement</u> | <u>Restricted</u> | <u>Registration</u> |
| <u>May 29, 2023</u> | <u>Issuance</u> | <u>18,000,000</u> | <u>Common</u> | .001 | <u>no</u> | Kelli Austin | <u>Consulting Contract</u> | <u>Restricted</u> | <u>Registration</u> |
| <u>May 29, 2023</u> | <u>Conversion</u> | <u>(21,259)</u> | <u>Series D</u> | .001 | <u>no</u> | Crowd Funding Series D conversion | <u>Debt Exchange</u> | <u>Restricted</u> | <u>Registration</u> |
| <u>May 29, 2023</u> | <u>Conversion</u> | <u>2,548,680</u> | <u>Common</u> | .001 | <u>no</u> | Crowd Funding Series D Conversion | <u>Debt Exchange</u> | <u>Restricted</u> | <u>Registration</u> |
| <u>July 1, 2023</u> | <u>Conversion</u> | <u>(4,000,000)</u> | <u>Series B</u> | .001 | <u>no</u> | Harry Zhabilov | <u>Conversion</u> | <u>Restricted</u> | <u>Registration</u> |
| <u>July 1, 2023</u> | <u>Conversion</u> | <u>40,000,000</u> | <u>Common</u> | .001 | <u>no</u> | Harry Zhabilov | <u>Conversion</u> | <u>Restricted</u> | <u>Registration</u> |
| <u>August 23, 2023</u> | <u>Conversion</u> | <u>(200,000)</u> | <u>Series C</u> | .001 | <u>no</u> | Korr Acquisition Group. Kenny Orr | <u>Conversion</u> | <u>Restricted</u> | <u>Registration</u> |
| <u>August 23, 2023</u> | <u>Conversion</u> | <u>20,000,000</u> | <u>Common</u> | .001 | <u>no</u> | Kenny Orr | <u>Conversion</u> | <u>Restricted</u> | <u>Registration</u> |
| <u>August 31, 2023</u> | <u>Conversion</u> | <u>(5,300,000)</u> | <u>Series B</u> | .001 | <u>no</u> | Mt Rose, Valentin Dimitrov | <u>Conversion</u> | <u>Restricted</u> | <u>Registration</u> |
| <u>August 31, 2023</u> | <u>Conversion</u> | <u>53,000,000</u> | <u>Common</u> | .001 | <u>no</u> | Valentin Dimitrov | <u>Conversion</u> | <u>Restricted</u> | <u>Registration</u> |
| <u>October 31, 2023</u> | <u>Conversion</u> | <u>51,726,190</u> | <u>Common</u> | .0001 | <u>no</u> | Equity Market Advisors Steve Apolant | <u>Conversion</u> | <u>Restricted</u> | <u>Registration</u> |
| <u>October 31, 2023</u> | <u>Conversion</u> | <u>37,447,034</u> | <u>Common</u> | .0001 | <u>no</u> | Sky_Direct Steve Apolant | <u>Conversion</u> | <u>Restricted</u> | <u>Registration</u> |

Shares Outstanding on Date of This Report:

Common: 3,172,974,957
Preferred A: 60,000,000
Preferred B: 442,880,000
Preferred C: 3,452,907
Preferred D: 0
Preferred E: 0



Example: A company with a fiscal year end of December 31st 2023, in addressing this item for its Annual Report, would include any events that in changes to any class of its outstanding shares from the period beginning on January 1, 2022 through December 31, 2023 pursuant to the tabular format above.

*****Control persons for any entities in the table above must be disclosed in the table or in a footnote here.**

Use the space below to provide any additional details, including footnotes to the table above

B. Promissory and Convertible Notes

Indicate by check mark whether there are any outstanding promissory, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities:

No: ☐ Yes: x (If yes, you must complete the table below)

| Date of Note Issuance | Outstanding Balance (\$) | Principal Amount at Issuance (\$) | Interest Accrued (\$) | Maturity Date | Conversion Terms (e.g. pricing mechanism for determining conversion of instrument to shares) | Name of Noteholder. *** You must disclose the control person(s) for any entities listed. | Reason for Issuance (e.g. Loan, Services, etc.) |
|-----------------------|--------------------------|-----------------------------------|-----------------------|------------------|--|---|---|
| <u>11/01/2022</u> | <u>283,000</u> | <u>\$283,000</u> | <u>\$11,320</u> | <u>11/1/2023</u> | <u>Converts into 56,600,000 shares of common stock at .005 per share</u> | <u>Camelot Nevada Trust</u> <u>Kelli Austin, Trustee</u> | <u>Loan</u> |

*****Control persons for any entities in the table above must be disclosed in the table or in a footnote here.**

Use the space below to provide any additional details, including footnotes to the table above:

****The terms of this convertible note are in dispute. Both parties have signed a Stand Still Agreement in an attempt to resolve this matter amicably. The dispute was resolved in the first quarter of 2024.**

4) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations. Ensure that these descriptions are updated on the Company's Profile on www.OTCMarkets.com.

A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

Enzolytics, Inc. is a Delaware corporation in the development stage. The Corporation was initially incorporated, under the name of T and T Homes Limited on July 28, 2004, in the United Kingdom. On November 25, 2004, the name of the Corporation was amended to be Falcon Media Services, Ltd. On November 12, 2008, the Company changed its name to Extreme Mobile Coatings Corp., Ltd. On March 2, 2009, the Company changed its name to Extreme Mobile Coatings Worldwide Corp. On May 19, 2010, the Company changed its name to Structural Enhancement Technologies Corp. Lastly, on November 16, 2012, the Company amended its name to Eco- Petroleum Solutions, Inc. to indicate a change in its business plan to expand its operations by entering into the renewable energy sector to conduct the business of blending, bottling, and distributing private label motor oil, transmission fluid, and related products for the automotive aftermarket.

OTC Markets Group Inc.

On July 21, 2017, the Company submitted a Corporate Action requesting a name and symbol change, as required by the merger agreement, to change the name of the Company from Eco-Petroleum Solutions, Inc. to Immunotech Laboratories, Inc. to indicate the Company's entrance into the Drug Development Industry for Immunotherapies. The request was subsequently withdrawn, and the merger agreement terminated.

On October 25, 2017, the Company's subsidiary Immunotech Laboratories, Inc. submitted a request to for the retirement of the Immunotech Laboratories, Inc. symbol IMMB from the OTC Market. The request was subsequently denied, and a deficiency letter issued resulting in the termination of the merger agreement with ECPO. As a result of the merger termination, IMMB is a wholly separate entity from Enzolytics, Inc.

On January 15, 2018, the merger agreement with Immunotech Laboratories, Inc. was terminated except for Section 1.03(d)(i) which relates to the appointment of Harry Zhabilov as Chairman and CEO of ECPO which remained in effect.

On January 30, 2018, a new Corporate action was filed by the Company to change its name from Eco-Petroleum Solutions, Inc. to Enzolytics, Inc. to better represent the new business strategy. The Corporate action was approved on March 22, 2018, and the ticker symbol was changed from ECPO to ENZC. The amendment to the Articles of Incorporation in the state of Delaware were filed on January 17, 2018 changing the name to Enzolytics, Inc.

On March 26, 2018 an asset purchase agreement was entered with Immunotech Laboratories, Inc whereby the Exclusive License Agreement for the Patented Immunotherapy Treatment for the care of HIV/Aids and Hepatitis C patients, the Forty Nine Percent ownership in Immunotech Laboratories BG, all equipment and licensing of intellectual property associated with the Patented treatment in exchange for a secured note receivable, common stock of Enzolytics, Inc. issued to Immunotech Laboratories, Inc. and assumption of certain debt from Immunotech by Enzolytics, Inc.

On June 25, 2018, the Company entered into a settlement agreement and stipulation ("Settlement Agreement") with Livingston Asset Management LLC ("Livingston") in connection with the settlement of \$563,000 of bona fide obligations the Company owed to certain of its creditors. The Settlement Agreement was subject to Federal court fairness hearing, and on August 21, 2018, a Federal Court granted approval of the Settlement Agreement. If satisfied in full, pursuant to the Settlement Agreement the Company shall reduce the Company's debt obligations in exchange for the issuance of 563,000,000 shares of Company's common stock, in multiple tranches, pursuant to the terms of section 3(a)(10) of the Securities Act of 1933, as amended. At no time was Livingston allowed to beneficially own more than 9.99% of the Company's outstanding common stock. In connection with the transaction, the Company issued to Livingston a convertible promissory note in the principal amount of \$100,000 bearing interest of 10% per year to cover legal fees and other expenses. The Note was convertible into shares of the Company's common stock at 50% of the lowest closing bid price for 10 trading days prior to the date of conversion. Under the terms of a separate engagement letter, in connection with the settlement agreement, the Company was to pay a registered placement agent ten percent (10%) of the dollar amount of creditor obligations extinguished pursuant to the settlement agreement. As of March 31, 2020, 447,859,000 shares have been converted.

On April 30, 2020, the Company filed Foreign Profit Corporation Article of Continuance pursuant to Wyoming Statute W.S. 17-16- 1810 to redomicile the Company from Delaware to Wyoming and increasing the authorized common shares to three billion. On May 21, 2020, the Company was approved by the State of Wyoming.

On September 15, 2020, Enzolytics, Inc. and BioClonetics Immunotherapy, Inc., a biotech company located in Dallas, TX, announced the execution of a Letter of Intent to merge the two entities together with the intent to combine the two proprietary technologies to evaluate the beneficial and synergistic effect of combining therapeutics of the two entities to treat those infected with the HIV virus.

On October 22, 2020, the Company announced the appointment, by the Board of Directors of the Company, on October 20, 2020, of Charles Cotropia to the position of CEO of Enzolytics. Mr. Cotropia also serves as CEO of the Company's Merger target BioClonetics Immunotherapeutics, and Harry Zhabilov the former CEO of the Company has taken the position of CSO. Charles Cotropia was appointed to the Company's Board of Directors on October 1, 2020. Simultaneously, Harry Zhabilov was appointed to the BioClonetics Immunotherapeutics board.

On November 4, 2020, the Company elected to bring the Company back into good standing in Delaware rather than complete the redomicile to Wyoming.

On November 16, 2020, the issuer (having been renamed, immediately prior to this Holding Company Reorganization, from "Enzolytics, Inc." to "ENZC SUB, Inc.") completed a corporate reorganization (the "Holding Company Reorganization") pursuant to which ENZC SUB, Inc., as previously constituted (the "Predecessor") became a direct, wholly-owned subsidiary of a newly formed Delaware corporation, Enzolytics, Inc. (the "Holding Company"), which became the successor issuer. In other words, the Holding Company is now the public entity. The Holding Company Reorganization was effected by a merger conducted pursuant to Section 251(g) of the Delaware General Corporation Law (the "DGCL"), which provides for the formation of a holding company without a vote of the stockholders of the constituent corporations.

In accordance with Section 251(g) of the DGCL, Enzolytics Merger Corp. ("Merger Sub"), another newly formed Delaware corporation and, prior to the Holding Company Reorganization, was an indirect, wholly owned subsidiary of the Predecessor, merged with and into the Predecessor, with the Predecessor surviving the merger as a direct, wholly

owned subsidiary of the Holding Company (the “Merger”). The Merger was completed pursuant to the terms of an Agreement and Plan of Merger among the Predecessor, the Holding Company and Merger Sub, dated November 16, 2020 (the “Merger Agreement”).

As of the effective time of the Merger and in connection with the Holding Company Reorganization, all outstanding shares of common stock and preferred stock of the Predecessor were automatically converted into identical shares of common stock or preferred stock, as applicable, of the Holding Company on a one-for-one basis, and the Predecessor’s existing stockholders and other holders of equity instruments, became stockholders and holders of equity instruments, as applicable, of the Holding Company in the same amounts and percentages as they were in the Predecessor prior to the Holding Company Reorganization.

The executive officers and board of directors of the Holding Company are the same as those of the Predecessor in effect immediately prior to the Holding Company Reorganization. For purposes of Rule 12g-3(a), the Holding Company is the successor issuer to the Predecessor, now as the sole shareholder of the Predecessor. Accordingly, upon consummation of the Merger, the Holding Company’s common stock was deemed to be registered under Section 12(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 12g-3(a) promulgated thereunder.

The Holding Company adopted a certificate of incorporation (the “Certificate”) and bylaws (the “Bylaws”) that are, in all material respects, identical to the certificate of incorporation and bylaws of the Predecessor immediately prior to the Holding Company Reorganization, with the possible exception of certain amendments that are permissible under Section 251(g)(4) of the DGCL. The Holding Company has the same authorized capital stock and the designations, rights, powers and preferences of such capital stock, and the qualifications, limitations and restrictions thereof are the same as that of the Predecessor’s capital stock immediately prior to the Holding Company Reorganization.

The common stock of the Holding Company trades on OTC Markets under the symbol “ENZC” under which the common stock of the Predecessor was previously listed and traded. As a result of the Holding Company Reorganization, the common stock of the Predecessor will no longer be publicly traded.

On November 30, 2020, Enzolytics, Inc. (the “Company”) entered into a Business Combination Agreement with Bioclonetics Immunotherapeutics, Inc., (“Bioclonetics”) a Texas Corporation controlled by Charles S. Cotropia, the Company’s current Chief Executive Officer.

As consideration for the Business Combination, and in exchange for 100% of the issued and outstanding stock of BioClonetics, the Company has agreed to issue a total of 204,430,000 newly issued shares of Series B Preferred Stock to Charles S. Cotropia, and other Bioclonetics Designees and 90,570,000 shares of newly issued Series B Preferred Stock to Harry Zhabilov, the Company’s current Chief Financial Officer. These shares were issued on December 7, 2020.

In addition, on November 30, 2020, the Zhabilov Trust, the Company’s Controlling Shareholder, entered into a Control Block Transfer Agreement, under which the Zhabilov Trust has agreed to transfer 35,100,000 shares of Series A Preferred Stock (the “Control Block”) to Charles S. Cotropia and other Bioclonetics Designees. This reallocation of shares from Zhabilov Trust was completed on December 31, 2020.

After such share issuances and transfers were completed, Charles S. Cotropia became the Company's new Control Block holder and majority shareholder, in addition to his role as Chief Executive Officer of Enzolytics, Inc., resulting in a Change of Control.

In addition, on November 16, 2020 the Company entered into debt exchange agreements with Seacor Capital, Inc., and Sky Direct, LLC whereby the balance of their outstanding notes and accrued interest were exchanged for Preferred Series C shares of ENZC extinguishing the debt obligation.

As a result of the reorganization, in accordance with Section 251(g) of the DGCL, the remaining convertible and non-convertible debt of ENZC is now debt of the Predecessor and payable by or convertible into shares of the non-public subsidiary.

Pursuant to the terms of the Business Combination Agreement, on November 24, 2020, the Company formed two new Texas corporations as wholly-owned subsidiaries for the purpose of licensing certain patented technologies: Biogenysis, Inc. and Virogenitics, Inc.

On August 15, 2022, the company signed a lease its new physical address and telephone number, 1101 Raintree Circle, Suite 130 Allen, Texas 75013, telephone number, (972) 292-9414.

Patent License Agreement

Also on November 30, 2020, Virogenitics, Inc., a wholly-owned subsidiary of Enzolytics, Inc., entered into a Patent License Agreement with the Zhabilov Trust in order to license the U.S. Patent No. 7,479,538, entitled Irreversibly - Inactivated pepsinogen fragment and Pharmaceutical composition the same for detecting preventing and treating HIV; U.S. Patent No. 8,066,982, Irreversibly - Inactivated pepsinogen fragment and Pharmaceutical composition compressing the same for detecting preventing and treating HIV, including all patents issuing therefrom and any foreign counterpartsthereof.

Provisional Patent for Immunotherapy Treatment of Multiple Sclerosis

On December 9, 2020 the company filed a provisional patent with the U.S. Patent Office for an Immunotherapy treatment of Multiple Sclerosis developed by Harry Zhabilov, titled NUCLEAR PROTEINS ISOLATED FROM MAMALIAN SPINAL CORD (SCNP) IMMUNE FACTOR, Ser. No. 62/123341. The Company received confirmation of filing from the U.S. Patent Office on December 10, 2020. On January 19, 2021 the Company announced the receipt for the Multiple Sclerosis Patent Application.

Engagement of BTS Research for Planned Toxicity Test

On December 14, 2020, the Company engaged SAMM SOLUTIONS, INC. (DBA BTS Research), through a Master Service Agreement ("MSA"), to conduct a toxicity study on the Company's Flagship compound ITV-1. The Company has previously tested the compound in successful Clinical Trials in Bulgaria, but FDA regulations require separate Toxicity tests before an Investigational New Drug process may begin in the United States. The Company is still in the planning stages and based on the Mutual Recognition Agreement between the European Medicines Agency and the U. S, Federal Drug Administration may pre-empt the need for additional planned toxicity study. The toxicity started on June 1, 2022.

Texas A&M Facilities

Effective December 1, 2020, the Company, through Bioclonetics, entered a lease with Texas A & M University for office and laboratory space on the campus of Texas A&M University in the University's Institute for Preclinical Studies in order to expand the Company's development capabilities for the production of additional monoclonal antibodies.

PCAOB AUDITORS

On January 11, 2021, the Company engaged Malone Bailey to perform the Audit for the years ended December 31, 2019 and 2020. The Company completed the client approval process in early February. No unanswered accounting issues arose. It was determined in June of 2021 that the Bioclonetics transaction, which closed in November of 2020, should be accounted for as a reverse merger rather than a business combination and will be reported as such in the audited financials for ENZC. The requested change in accounting method required the books and records of Bioclonetics to be audited for the years ended December 31, 2019 and 2020 in accordance with GAAP standards by a PCAOB auditor.

After the hiring of independent Accounting Consultants, it was determined that the Companies did do a business combination not a reverse merger, and as of the time of this filing, the Company has provided all the records and agreements, accounting memos and backup documentation requested by the consultant and the auditor. The Changes in Accounting Method will result in amendments to the quarters ending March 31, 2021, June 30, 2021, and September 30, 2021 immediately upon completion of the audits. In July of 2022, the Company and Malone Bailey terminated their relationship. There were no unresolved accounting or financial issues between the parties. Gries and Associates, LLC was retained on July 18, 2022, and completed the 2020-2021 audit on December 16, 2022. Gries and Associates were engaged in January 2023 to perform the 2022 Audit, which is currently underway.

Discovery of Seven Newly Identified Conserved Target Sites of the HIV Virus.

On February 1, 2021, the Company announced the discovery, using Artificial Intelligence, seven new expected immutable sites on the virus.

In Vitro Test Results for IPF Against Human Corona Virus 229E Strain (HCoV-229E)

In Vitro test result on the IPF peptide treatment against human corona virus strain 229-E from the Bulgarian National Centre of Infectious and Parasitic Diseases conducted by Petia Genova-Kalou were reported on February 16, 2021. The test results exhibited comparable efficiency but with 20-fold lower toxicity than the widely used anti-influenza medicine, Tamiflu.

In Vitro Test Results for IPF Against Herpes Simplex Virus (HSV-1)

In-Vitro test results from the Bulgarian National Centre of Infectious and Parasitic Diseases conducted by Petia Genova- Kalou were reported on February 16, 2021, on the IPF peptide (IPF). The tests did not show toxicity to cells and effectively inhibited the infectious HSV-1 virus. Furthermore, it was more effective than Acyclovir and had no toxicity effects on Acyclovir.

Formation of International Medical Partners (IMPL) a Bulgarian Limited Liability Company

OTC Markets Group Inc.

On February 22, 2021, the Company, along with its Bulgarian Partners, executed the Articles of Association to form International Medical Partners. The Company is a 50% owner of IMPL. Clinical Trial under the European Medicines Agency guidelines for the ITV-1 compound are being planned which the Bulgarian Partners are funding. The Company will be providing the necessary vials for testing. On May 7, 2021, the certificate of incumbency with the required apostille was received by IMPL and the final step necessary for the completion of the registration in Bulgaria was completed.

Distribution and Operational Agreement with IMPL

On March 16, 2021, the Company finalized the operational agreement with IMPL and a distribution agreement for the territories of the Member Countries of the European Medical Agency and the countries of Russia, Georgia, Ukraine, Moldova, Belarus, Armenia, Azerbaijan, Kazakhstan, Uzbekistan, Turkmenistan, Kyrgyzstan, Tajikistan, Estonia, Latvia, and Lithuania.

Issuance of Distributorship for India and multiple Eastern European Countries.

On May 12, 2021, the Company granted a distributorship license to a European pharma entity giving it the right to distribute the Company's anti-HIV-1 therapeutic ITV-1 in the countries of India, Pakistan, UAE, Indonesia, Philippines, Nigeria, Benin and Togo, Kenya, Tanzania, Rwanda, Libya, Uganda, North Sudan, Egypt, Morocco, and Tunisia. The Licensing Entity is the owner of a pharmaceutical plant in Eastern Europe. Pursuant to the Agreement, Enzolytics will receive \$1 Million USD and 50% ownership in the Licensing Entity valued at \$8 Million. The License is granted with a commitment by the Licensee to sale and distribute the ITV-1 therapeutic in the Licensed Territory. In addition, the Licensing Entity has invested \$2 Million USD in the Company in exchange for Company Preferred Series E stock bringing to the Company \$3 Million in cash plus a 50% ownership in the Licensing Entity. This agreement will result in establishing a committed partner for sale and distribution of the Company's ITV-1 therapeutic in the Licensed Territory as well as 50% ownership in Licensee and its profit derived from sales in the Licensed Territory.

Enzolytics, Inc. and Intel Corporation White Paper on Use of Artificial Intelligence

On May 17, 2021, Enzolytics Inc. and Intel Corporation published a thought leadership collaboration. The white paper titled, "Optimizing Empathetic A.I. to Cure Deadly Diseases," highlights Intel's Artificial Intelligence Analytic tools and Enzolytic's innovative approach and groundbreaking contributions to create universal, durable, and broadly effective treatment targeting all virus variants.

Discovery of Conserved Immutable Target Sites on HTLV-1 Virus

The Company announced on May 26, 2021, that it had identified conserved, expectedly immutable sites on the HTLV-1 virus against which it will produce targeted anti-HTLV-1 monoclonal antibodies (mAbs). There are no effective vaccines against HTLV-1 and no antiviral drugs available for treating infections caused by the virus. Utilizing the Company's proprietary Artificial Intelligence (AI) methodology, conserved target sites have now been identified against which fully human anti-HTLV-1 monoclonal antibodies will be produced in its lab on the campus of Texas A&M University in the University's Institute for Preclinical Studies.

Additional Subscription of Preferred Series C

In February, 2021, Enzolytics CEO invested \$200,000.00 in a subscription for Series C Preferred shares.

On June 6, 2021, Enzolytics CEO invested an additional \$100,000.00 in a subscription for Series C Preferred shares.

Enzolytics, Inc. and International Medical Partners Ltd Engage Pharmalex, Clinic Design, Ltd. and Danhson Ltd for ITV-1 Clinical Trials and Permitting Process

On June 14, 2021, the Company announced the engagement by International Medical Partners Ltd (“IMPL”) of the Contract Research Organization (CRO) Clinic Design, Ltd and PharmaLex to prepare and establish a drug development program for the creation of protocols for human clinical trials that will lead to the licensing of the Company's ITV-1 therapeutic under the European Medicine Agency (EMA). The Company has contracted Danhson Ltd. to produce the initial quantities of ITV-1 to be used for preclinical and clinical trial purposes.
VetProm Site Visit

On July 22, 2021, Chief Science Officer, Harry Zhabilov (“Zhabilov”) completed ENZC’s second visit to Sofia, Bulgaria where Zhabilov and ENZC’s Bulgarian and US Consultants toured the manufacturing facility of VetProm, JSC (VetProm”) , a wholly owned subsidiary of Danhson, LTD. This facility will be producing the ITV-1 compound for the clinical trials being conducted by Clinic Design Ltd. and all ENZC’s future production needs. ENZC has purchased and shipped specialized equipment for installation at the facility as part of the manufacturing line for the ITV-1 immunotherapy treatment as well as the raw materials needed for the first clinical trial batch.

Appointment of Steve Sharabura as President of RobustoMed

On July 26, 2021 Steve Sharabura was appointed President of RobustoMed, Inc. RobustoMed received initial funding on November 12, 2021 for the implementation of its business plan to develop international markets for the Company’s products in Central and Latin America.

Agreement entered with Danhson and Clinic Design for Clinical Trials

Enzolytics, Inc. completed arrangements and agreements with Danhson (<https://danhson.bg/en/>) and Clinic Design (<https://clinicdesign.eu/>) on July 29, 2021 to advance its anti-HIV therapeutic ITV-1 to production and clinical trials. These steps are prefatory to approval by the European Medicines Agency (EMA), leading to patient use authorization.

Master Service Agreement (“MSA”) and Product Specific Agreement – Development and Manufacturing Services (“PSA”) entered into between Samsung Biologics Co., LTD. and Enzolytics, Inc.

On October 7, 2021, the Company entered into a MSA and PSA with Samsung Biologics Co., Ltd to advance the development of the Company’s human clone antibody program and clinical testing.

Installation of Equipment at VetProm Facility

Enzolytics, Inc. purchased and installed equipment necessary for production of the ITV-1 immunotherapy for the clinical trials being design by Clinic Design. The original equipment had to be returned because of damage to the

centrifuge which, along with other issues encountered by IMPL, delayed the scheduled production expected in October. The new expected production date has been rescheduled for January of 2022.

Initial Funding for RobustoMed, Inc.

On November 12, 2021 RobustoMed, Inc. received the first funding for use in the implementation of its business plan to establish a foothold in Latin and Central America.

Enzolytics, Inc. Announces Production and Sale in North America of "Enzolytics IPF Immune", a dietary liquid supplement based on U.S. Patent No. 8,309,072.

On November 17, 2021, announced planned production and sale in the U.S. and North America of "Enzolytics IPF Immune", a liquid nutritional supplement. Enzolytics IPF Immune (Irreversible Pepsin Fraction) isolated from hydrolyzed pepsin. Enzolytics IPF Immune is beneficial for health Enzolytics IPF Immune is a nutritional dietary supplement supporting the immune system thus beneficial for health Product is used to promote health, supports normal immune function used to maintain healthy body IPF Immune could be used as an immune supporter. Product is natural and tested for safety. Enzolytics IPF Immune is registered under NDI # 1083, Patent # 8,309,072 The active components in the supplement have been registered with the FDA for use in the U.S. under NDI reg. no. 1083. The product will be produced and sold by the Company pursuant to its license under U.S. Patent No. 8,309,072 (the '072 Patent).

Enzolytics Reports Its Engagement of Scendea USA, Inc., a Leading International Product Development and Regulatory Consulting Group, To Guide the Progress Toward Clinical Trials and Market Approval for Its ITV-1 Anti-HIV Therapeutic

On December 29, 2021, Enzolytics, Inc. engaged Scendea USA, Inc. (www.scendea.com), a leading international product development and regulatory consulting group, to advance its anti-HIV therapeutic ITV-1 to production, clinical trials, and market approval under both the European Medicines Act (EMA) and the U.S. FDA regulatory process. Scendea is a leading product development and regulatory consulting group serving the pharmaceutical and biotechnology industry. Scendea's service will focus on reducing time-to-market and minimizing development costs. Enzolytics, Inc. Announces Production and Sale in North America of "Enzolytics IPF Immune(TM)", A New Dietary Supplement That Enhances the Immune System

January 4, 2022, the Company announced the production and sale in the U.S. and North America of "Enzolytics IPF Immune™", a science-backed liquid nutritional supplement that acts to strengthen the body's immune system.

Enzolytics Announces Its New Technology for Entry Into The In-Vitro Diagnostics Market

Enzolytics announced its plans for entry into the diagnostics market on February 21, 2022. The Company filed a comprehensive U.S. and foreign Patent Cooperation Treaty (PCT) Patent Application covering its invention of a novel, innovative technology for improved diagnostics. The PCT Application covers the Company's identification of highly conserved antigens and epitopes of SARS-CoV-2 that can be used in vaccines and to produce binding proteins (e.g., antibodies) for treating, preventing, or reducing the risks of infections caused by β -coronaviruses such as SARS-CoV-2. The patent also covers the discovery of using these identified antigens and epitopes as targets for detecting and diagnosing SARS-CoV-2 infection.

Enzolytics, Inc. Announces New Advisory Board Member

On February 28, 2022, Dr. Suraj Kumar Saggar accepted an invitation from the Company to join its Advisory Board. Dr. Saggar brings to the Company his vast experience as a physician and healthcare research professional with an established track record of exceptional performance in healthcare operations, clinical trials, and regulatory compliance.

Enzolytics IPF Immune (TM), a nutritional supplement, Is Introduced into the U.S. Market

On March 10, 2022, the Company announced that Enzolytics IPF Immune™, a nutritional supplement, will be introduced into the U.S. market in late March 2022.

Enzolytics, Inc.'s Wholly Owned Subsidiary Virogenetics, Inc. Reports Progress on the Delivery of its ITV-1 Anti- HIV Therapeutic for Use by Patients in African Regions

On March 14, 2022, the wholly owned subsidiary Virogenetics, Inc. (the "Subsidiary") of Enzolytics announced its progress toward the production and use of its ITV-1, anti-HIV immunotherapy treatment in the Central and Eastern regions of Africa for patients with HIV/AIDS.

The steps necessary for the production and delivery of the Company's anti-HIV therapy in these regions are in progress. Toxicology, pharmacodynamic and pharmacokinetic studies (toxicology studies) of the immunotherapy are planned, a prerequisite to use of the immunotherapy in certain African countries where the therapies will be used.

Enzolytics Announces the Discovery of Conserved Target Sites on the Monkeypox Virus.

On June 21, 2022, Enzolytics announced discovery of conserved target sites on the Monkeypox Virus. The company also announced that these discoveries are a part of Enzolytics' continuing efforts to address future healthcare needs in pandemics using its Comprehensive Artificial Intelligence (AI) protocol for producing Monoclonal Antibodies, including implementing AI analysis of existing viruses and any new virus immediately upon its emergence globally.

Enzolytics Highlights Its Comprehensive PCT Patent Applications Covering Discovered Conserved Target Epitopes on the SARS- CoV-2 and HIV Viruses

In the submissions, under the Patent Cooperation Treaty (PCT), Enzolytics, Inc. has pending in its international patent applications, covering the use of any of its discovered numerous conserved Coronavirus epitopes or conserved HIV epitopes in the production of monoclonal antibodies, the production of vaccines or use in diagnostic tests for detecting the viruses in patients the applications allow the Company to prosecute the applications both in the U.S. and in all PCT member countries. The applications identify and claim the conserved, immutable sites on the SARS-CoV-2 virus and HIV virus that have been identified by the Company through its Artificial Intelligence (AI) technology.

Enzolytics Inc. Announces Collaboration with Abveris to Discover Monoclonal Antibodies

On September 16, 2022, Enzolytics, Inc announced a collaborated with Abveris, a division of Twist Bioscience Corporation, to discover fully human monoclonal antibodies against multiple viruses. The collaboration makes

possible the combination of the synergistic technologies of the two companies in discovering monoclonal antibodies against numerous pathogenic viruses.

Enzolytics Reports Successful Completion of an MTD Tolerability Study of Its ITV-1 anti-HIV Therapeutic Leading to the Completion 28- day GLP Toxicology Study

On October 5, 2022 Enzolytics announced the completion of the first phase of the animal toxicology studies on its ITV-1 anti-HIV therapeutic and completed the GLP Compliant 28-day Repeat Dose Toxicity Study which is being used part of the ITV-1 African product.

New Advisory Board Member

On October 24, 2022, the Company announced appointing Dr. Kirsten Bischof to the Company's advisory Board. Dr. Bischof brings the Company her vast experience as a Surgeon and healthcare research professional with an established track record of exceptional performance in healthcare. Her appointment is a significant step as Enzolytics positions itself to strengthen its Artificial Intelligence (A.I.) platform. She will assist Enzolytics in identifying innovative early biomarkers for critical care monitoring and advanced hemodynamic management.. In addition, she has been working with the Company's collaborators in Estonia to develop this platform for assessing the effects of nutrition, genetics, and microbiome on diseases.

Partnership announcement with Contenta Ltd. And Khalpey AI lab for Alzheimers Disease.

On September 5th, 2023 Biogenysis, Inc. a wholly owned subsidiary of Enzolytics, Inc. announced Partnership with Khalpey AI Lab and Contenta, Ltd. to Incorporate AI in Microbiome Analysis to Identify Biomarkers for Use in Accurately Predicting Alzheimer's Disease Onset and Prevention.

Execution of Business Combination Agreement with Sagaliam Acquisition Corp. (NASDAQ:SAGA)

On September 18, 2023, the Company executed a definitive business combination agreement with Sagaliam Acquisition Corp. selling the operating subsidiaries Virogenetics, Inc. and Biogenysis, Inc. in a stock transaction valued at \$450 million.

B. List any subsidiaries, parent company, or affiliated companies.

The Company is a 49% owner of the Bulgarian entity IMMB BG, which held a sub-license agreement issued by ENZC for the proprietary immunotherapy treatment until it was terminated in the second quarter of 2021 and the investment written off as worthless in the yearend 2021 financials.

The Company is 100% owner of RobustoMed, Inc.

The Company is 100% owner of BioClonetics Immunotherapy, Inc.

The Company is 50% owner of International Medical Partners Ltd a Bulgarian entity.

C. Describe the issuers' principal products or services.

On September 18, 2023, the Company executed and closed a definitive business combination agreement with Sagaliam Acquisition Corp. selling the operating subsidiaries Virogenetics, Inc. and Biogenysis, Inc. in a stock transaction valued at \$450 million. This left the Company with no operating subsidiaries. The Company is currently formulating a new business strategy and searching for target acquisitions.

5) Issuer's Facilities

The goal of this section is to provide investors with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer. Describe the location of office space, data centers, principal plants, and other property of the issuer and describe the condition of the properties. Specify if the assets, properties, or facilities are owned or leased and the terms of their leases. If the issuer does not have complete ownership or control of the property, describe the limitations on the ownership.

The Company signed a lease for a new lab and business facility at 1101 Raintree Circle, Suite 130, Allen, Texas 75013 All lease payments are current.

In addition, the Company leases a 695 sq ft office and laboratory facility located at 800 Raymond Stotzer Parkway Building 1904, Suite 2106, College Station, Texas 77843 for \$2,595.00 per month. The lease ends in December 2023. The lease is currently month to month. All lease payments are current.

6) All Officers, Directors, and Control Persons of the Company

Using the table below, please provide information, as of the period end date of this report, regarding all officers and directors of the company, or any person that performs a similar function, regardless of the number of shares they own.

In addition, list all individuals or entities controlling 5% or more of any class of the issuer's securities.

If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity. Include Company Insiders who own any outstanding units or shares of any class of any equity security of the issuer.

The goal of this section is to provide investors with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial owners.

| Names of All Officers, Directors, and Control Persons | Affiliation with Company (e.g. Officer Title /Director/Owner of 5% or more) | Residential Address (City / State Only) | Number of shares owned | Share type/class | Ownership Percentage of Class Outstanding | Names of contr person(s) if a corporate entity |
|---|---|---|------------------------|------------------|---|--|
| Harry Zhabilov | CFO/CSO/Secretary/Director | <u>Frisco, Texas</u> | <u>184,450,000</u> | <u>Series B</u> | <u>41.64</u> | |
| Zhabilov Trust | Shareholder | <u>Frisco, Texas</u> | <u>7,200,000</u> | <u>Series A</u> | 54.54 | Diana Zhabilov Trustee |
| Charles S. Cotropia | CEO/Director (removed on 3-25-2024) | <u>Heath, Texas</u> | 68,143,334 | <u>Series B</u> | 15.39 | |
| <u>Joseph Cotropia</u> | <u>CSO</u> (removed on 3-25-2024) | <u>College Station, Texas</u> | 68,143,334 | <u>Series B</u> | <u>15.39</u> | |
| <u>Gaurav Chandra</u> | <u>COO</u> (Removed on March 25, 2024) | <u>Cape Town, South Africa</u> | 68,143,332 | <u>Series B</u> | 15.39 | |
| <u>Steven G. Sharabura</u> | <u>CEO</u> | <u>Atlanta GA.</u> | <u>N/A</u> | <u>N/A</u> | <u>N/A</u> | |
| <u>Lachezar Ivanov</u> | <u>Director</u> | <u>Sofia, Bulgaria</u> | <u>1,000,000</u> | <u>Series B</u> | <u>.23</u> | |
| <u>Diana Zhabilov</u> | <u>CFO</u> | <u>Frisco, Texas</u> | <u>N/A</u> | <u>N/A</u> | <u>N/A</u> | |
| | | | | | | |

Confirm that the information in this table matches your public company profile on www.OTCMarkets.com. If any updates are needed to your public company profile, log in to www.OTCIQ.com to update your company profile.

7) Legal/Disciplinary History

A. Identify and provide a brief explanation as to whether any of the persons or entities listed above in Section 6 have, in the past 10 years:

1. Been the subject of an indictment or conviction in a criminal proceeding or plea agreement or named as a defendant in a pending criminal proceeding (excluding minor traffic violations);

2. Been the subject of the entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, financial- or investment-related, insurance or banking activities;

Joseph Cotropia: On February 13, 2015, The Texas Medical Board revoked Cotropia's license to practice medicine and he was found to have failed to comply with required standards of care for the treatment of chronic pain. This revocation was based on an administrative law judge's findings that Cotropia violated the Medical Practices Act and TMB rules by prescribing opioids and other controlled substances that were not therapeutic, by failing to maintain records that supported the prescribed therapeutic regime, for inadequately supervising midlevel providers, and working at an unregistered, uncertified pain management clinic. This became final on March 17, 2015.

None

3. Been the subject of a finding, disciplinary order or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, a state securities regulator of a violation of federal or state securities or commodities law, or a foreign regulatory body or court, which finding or judgment has not been reversed, suspended, or vacated;

None

4. Named as a defendant or a respondent in a regulatory complaint or proceeding that could result in a "yes" answer to part 3 above; or

None

5. Been the subject of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

Joseph Cotropia: On February 13, 2015, The Texas Medical Board revoked Cotropia's license to practice medicine and he was found to have failed to comply with required standards of care for the treatment of chronic pain. This revocation was based on an administrative law judge's findings that Cotropia violated the Medical Practices Act and TMB rules by prescribing opioids and other controlled substances that were not therapeutic, by failing to maintain records that supported the prescribed therapeutic regime, for inadequately supervising midlevel providers, and working at an unregistered, uncertified pain management clinic. This became final on March 17, 2015.

6. Been the subject of a U.S Postal Service false representation order, or a temporary restraining order, or preliminary injunction with respect to conduct alleged to have violated the false representation statute that applies to U.S mail.

None

B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party to or of which any of their property is the subject. Include the name of the court or agency in which the

proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

The Company has pending litigation over disputed shares in California, and litigation in Delaware as to the appropriate party to a suit in Delaware. The Company is vigorously defending itself in these matters.

8) Third Party Service Providers

Provide the name, address, telephone number and email address of each of the following outside providers. You may add additional space as needed.

Confirm that the information in this table matches your public company profile on www.OTCMarkets.com. If any updates are needed to your public company profile, update your company profile.

Securities Counsel (must include Counsel preparing Attorney Letters).

Name: Morgan Petitti
Firm: Morgan E. Petitti, ESQ
Address 1: 118 W. Streetsboro Rd.
Address 2: Hudson, Ohio 44236
Phone: 330-697-5848
Email: Petittilaw@gmail.com

Accountant or Auditor

Name: Jona Barnes, E.A. Partner
Firm: Mallet & Barnes Tax Service
Address 1: 6136 Mission Gorge Road Suite 125
Address 2: San Diego, CA 92120
Phone: 619-326-0840
Email: jonabarnes117@gmail.com

Investor Relations

Name: N/A
Firm: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

All other means of Investor Communication:

Twitter: N/A
Discord: _____
LinkedIn: _____
Facebook: _____
[Other]: _____

Other Service Providers

Provide the name of any other service provider(s) that **that assisted, advised, prepared, or provided information with respect to this disclosure statement.** This includes

counsel, broker-dealer(s), advisor(s), consultant(s) or any entity/individual that provided assistance or services to the issuer during the reporting period.

Name: Steve Heuman
Firm: Eisner & Amper
Nature of Services: Consulting
Address 1: 111 Wood Avenue South
Address 2: Iselin, NJ 08830-2700
Phone: 212-949-8700
Email:

9) Disclosure & Financial Information

A. This Disclosure Statement was prepared by (name of individual):

Name: Camelot Nevada Trust
Title:
Relationship to Issuer: Consultant

B. The following financial statements were prepared in accordance with:

☐ IFRS
☒ U.S. GAAP

C. The following financial statements were prepared by (name of individual):

Name: Jona Barnes
Title: Enrolled Agent
Relationship to Issuer: Accountant
Describe the qualifications of the person or persons who prepared the financial statements:⁵

Provide the following qualifying financial statements:

- Audit letter, if audited;
- Balance Sheet;
- Statement of Income;
- Statement of Cash Flows;
- Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
- Financial Notes

Financial Statement Requirements:

- Financial statements must be published together with this disclosure statement as one document.
- Financial statements must be "machine readable". Do not publish images/scans of financial statements.
- Financial statements must be presented with comparative financials against the prior FYE or period, as applicable.
- Financial statements must be prepared in accordance with U.S. GAAP or International Financial Reporting Standards (IFRS) but are not required to be audited.

⁵ The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS and by persons with sufficient financial skills.

ENZOLYTICS, INC. AND SUBSIDIARIES
BALANCE SHEETS
(Unaudited)

| | December 31, 2023 | December 31, 2022 |
|--|---------------------|---------------------|
| ASSETS | | |
| Current assets: | | |
| Cash and cash equivalents | \$ 14,682 | \$ 554,169 |
| Investment in SAGA Shares | | |
| A/R Related party - Patten Energy, Inc., net of allowance for doubtful accounts of \$36,290 | - | - |
| Total current assets | <u>14,682</u> | <u>554,169</u> |
| Property and equipment, net | 106,372 | 128,460 |
| Other assets: | | |
| Deposit | 5,555 | 5,555 |
| Investment in Subsidiaries | <u>1,282,270</u> | <u>1,080,000</u> |
| Total other assets | <u>1,287,825</u> | <u>1,085,555</u> |
| | <u>\$ 1,408,878</u> | <u>\$ 1,768,184</u> |
| LIABILITIES AND SHAREHOLDERS' DEFICIT | | |
| Current liabilities: | | |
| Accounts payable | \$ 220,503 | \$ 236,573 |
| Accrued expenses and other current liabilities | 1,517,202 | 931,811 |
| Deferred income from Sale of Subsidiaries | | |
| Deferred Taxes Payable | | |
| Notes payable to investors, net of discount of \$0 and \$0 at December 31, 2023 and 2022, respectively | 417,300 | 600,213 |
| Crowdfunding convertible notes | 544,038 | 544,038 |
| Due to related parties: | | |
| Promissory note - Former director and officer | 35,000 | 35,000 |
| Officers, Directors and stockholders | 343,101 | 343,101 |
| License fee payable | 1,550,000 | 1,550,000 |
| Current liabilities - Discontinued Operations | <u>485,153</u> | <u>485,153</u> |
| Total current liabilities | <u>5,112,296</u> | <u>4,725,889</u> |
| Total long term liabilities | <u>866,452</u> | <u>866,452</u> |
| Total liabilities | <u>5,978,748</u> | <u>5,592,341</u> |
| Shareholders' Equity/(Deficit) | | |
| Preferred stock, Series A \$.0001 par value; 100,000,000 shares authorized, 60,000,000 issued and outstanding at December 31, 2023 and 2022, respectively | 6,000 | 6,000 |
| Preferred stock, Series B \$.0001 par value; 465,000,000 shares authorized, 447,180,000 and 445,180,000 issued and outstanding at December 31, 2023 and 2022, respectively | 44,288 | 45,418 |
| Preferred stock, Series C \$.0001 par value; 465,000,000 shares authorized, 3,452,097 and 941,078 issued and outstanding at December 31, 2023 and 2022, respectively | 345 | 94 |
| Preferred stock, Series D \$.0001 par value; 1,000,000 shares authorized, 0 and 0 issued and outstanding at December 31, 2023 and 2022, respectively | - | 2 |
| Preferred stock, Series E \$.0001 par value; 10,000,000,000 shares authorized, 2,500,000 and 0 issued and outstanding at December 31, 2023 and 2022, respectively | - | 500 |
| Common stock, \$.0001 par value; 3,000,000,000 shares authorized, 3,083,801,033 and 2,797,935,953 issued and outstanding at December 31, 2023 and 2022, respectively | 308,380 | 283,044 |
| Additional paid-in-capital | 29,256,896 | 26,900,052 |
| Preferred stock subscribed | 33 | 223 |
| Common stock subscribed | 12,809 | 12,809 |
| Additional paid-in-capital subscribed | 1,621,999 | 2,571,809 |
| Subscription receivable | (500,000) | (500,000) |
| Accumulated Deficit | <u>(35,320,620)</u> | <u>(33,144,108)</u> |
| Total shareholders' equity/(deficit) | <u>(4,569,870)</u> | <u>(3,824,157)</u> |
| Total liabilities and shareholders' deficit | <u>\$ 1,408,879</u> | <u>\$ 1,768,184</u> |

See accompanying notes to condensed consolidated financial statements.

ENZOLYTICS, INC. AND SUBSIDIARIES
CONSOLIDATED
STATEMENTS OF OPERATIONS
(Unaudited)

| | For the Year Ended December 31, 2023 | For the Year Ended December 31, 2022 |
|--|---|---|
| Continuing Operations: | | |
| Sales | \$ 52,796 | \$ - |
| Cost of Goods Sold: | | |
| Cost of Sales | - | - |
| Total cost of goods sold | - | - |
| Gross Profit | 52,796 | - |
| Expenses: | | |
| General and administrative | \$ 127,351 | \$ 419,849 |
| Salaries, wages and related costs | 126,263 | 732,131 |
| Consulting | 1,668,781 | 387,973 |
| Professional fees | 85,503 | 774,216 |
| Depreciation and amortization | 22,088 | 22,088 |
| Research and development | 171,609 | 567,874 |
| Total expenses | 2,201,594 | 2,904,131 |
| Loss from operations | (2,148,798) | (2,904,131) |
| Other income (expense): | | |
| Interest income | 2 | 60 |
| Sale of Subsidiary Stock | | |
| Interest expense | (27,716) | (37,315) |
| Total other income (expense) | (27,714) | (37,255) |
| Net income/(loss) | \$ (2,176,512) | \$ (2,941,386) |
| share | \$ (0.00) | \$ (0.00) |
| Weighted average shares outstanding - Basic and Diluted | 2,925,040,551 | 2,822,689,378 |

ompanying notes to condensed consolidated financial sta

ENZOLYTICS, INC. AND SUBSIDIARIES
Statements of Cash Flows
(Unaudited)

| | For the Year Ended December 31, 2023 | For the Year Ended December 31, 2022 |
|---|---|---|
| Cash flows from operating activities | | |
| Net loss | \$ (2,176,512) | \$ (2,941,386) |
| Adjustments to reconcile net loss to net cash provided by operating activities: | | |
| Non-cash expenses: | | |
| Depreciation | 22,088 | 22,088 |
| Stock based compensation | 1,430,800 | 22,750 |
| Obligations relating to assuming Crowdfunding Convertible Notes | \ | (250) |
| Changes in operating assets and liabilities: | | |
| Decrease in Accounts payable | (16,070) | |
| Deferred Income from sale of subsidiaries | 258,689,014 | |
| Decrease in notes payable | (182,913) | |
| Deferred Taxes | 100,601,283 | |
| Increase in SAGA shares | \$ (360,000,000) | |
| Increase (decrease) in accounts payable | (16,070) | (17,448) |
| Increase (decrease) in accrued expenses and other current liabilities | 585,391 | 253,456 |
| Net cash provided by operating activities | <u>(1,062,990)</u> | <u>(2,660,790)</u> |
| Cash flows from financing activities | | |
| Proceeds received from related parties - Directors and stockholders | - | (250,100) |
| Basis of Subsidiaries sold | (507,433) | |
| Issuance of equity | 29,469 | |
| Exercise of Series C Warrants | 8,917 | |
| Proceeds received from the issuances of notes payable from investors | 992,550 | 182,911 |
| Proceeds received from sale of Series E Preferred Stock | - | 1,000,000 |
| Net cash provided by financing activities | <u>523,503</u> | <u>932,811</u> |
| Decrease in cash | (539,487) | (1,727,979) |
| Cash at beginning of period | 554,169 | 2,282,148 |
| Cash at end of period | <u>\$ 14,682</u> | <u>\$ 554,169</u> |
| Supplemental Cash Flow Information: | | |
| Cash paid for interest | \$ 116 | \$ - |
| Cash paid for income taxes | \$ - | \$ - |
| Non-cash investing and financing activities | | |
| Conversion of crowdfunding notes into shares of Series D | \$ - | \$ 104,293 |
| Series B Preferred Stock for acquisition of subsidiary | \$ - | \$ 280,000 |

See accompanying notes to condensed consolidated financial statements.

Enzolytics, Inc. and Subsidiaries
Statement of Stockholder's Equity (Deficit)
For the Period from December 31, 2021 to September 30, 2023
(Unaudited)

| | Preferred Stock Series A Shares | Preferred Stock Series A Amount | Preferred Stock Series B Shares | Preferred Stock Series B Amount | Preferred Stock Series C Shares | Preferred Stock Series C Amount | Preferred Stock Series D Shares | Preferred Stock Series D Amount | Preferred Stock Series E Shares | Preferred Stock Series E Amount | Common Stock Shares | Common Stock Amount | Additional Paid-in Capital | Preferred Stock Subscribed | Common Stock Subscribed | Additional Paid-in Capital Subscribed | Earnings (Deficit) Accumulated | Total |
|---|---------------------------------------|--|---------------------------------------|--|---------------------------------------|--|---------------------------------------|--|---------------------------------------|--|------------------------|---------------------------|----------------------------------|----------------------------------|-------------------------------|--|--------------------------------------|-----------------------|
| Balance, December 31, 2021 | 60,000,000 | \$ 6,000 | 447,180,000 | \$ 44,718 | 941,078 | \$ 94 | - | \$ - | 2,500,000 | \$ 250 | 2,797,935,253 | \$ 279,794 | \$ 25,497,211 | 190 | \$ 12,809 | \$ 2,071,843 | \$ (30,202,722) | \$ (2,289,813) |
| Proceeds received for private placement | - | - | - | - | - | - | - | - | 2,500,000 | 250 | - | - | 999,750 | - | - | - | - | 1,000,000 |
| Stock issued for services | - | - | - | - | - | - | - | - | - | - | 32,500,000 | 3,250 | 19,500 | - | - | - | - | 22,750 |
| Stock issued for crowdfunding debt | - | - | - | - | - | - | 21,259 | 2 | - | - | - | - | 104,291 | - | - | - | - | 104,293 |
| Stock issued for investment in MMB | - | - | 7,000,000 | 700 | - | - | - | - | - | - | - | - | 279,300 | - | - | - | - | 280,000 |
| Stock subscribed for private placement | - | - | - | - | - | - | - | - | - | - | - | - | - | 33 | - | 499,966 | - | 500,000 |
| Net loss, December 31, 2022 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | (2,941,386) | (2,941,386) |
| Balance, December 31, 2022 | 60,000,000 | \$ 6,000 | 454,180,000 | \$ 45,418 | 941,078 | \$ 94 | 21,259 | \$ 2 | 5,000,000 | \$ 500 | 2,830,435,253 | \$ 283,044 | \$ 26,900,052 | 223 | \$ 12,809 | \$ 2,571,809 | \$ (33,144,108) | \$ (3,324,157) |
| Stock issued for services | - | - | - | - | - | - | - | - | - | - | 28,000,000 | 2,800 | 1,428,000 | - | - | - | - | 1,430,800 |
| Stock converted from preferred B to common | - | - | (11,300,000) | (1,130) | - | - | - | - | - | - | 113,000,000 | 11,300 | (10,170) | - | - | - | - | - |
| Stock converted from preferred C to common | - | - | - | - | (598,171) | (60) | - | - | - | - | 59,817,100 | 5,982 | (5,922) | - | - | - | - | (0) |
| Stock converted from preferred D to common | - | - | - | - | - | - | (21,259) | (2) | - | - | 2,548,680 | 255 | (253) | - | - | - | - | (0) |
| Stock converted from preferred E to common | - | - | - | - | - | - | - | - | (5,000,000) | (500) | 50,000,000 | 5,000 | (4,500) | - | - | - | - | - |
| Common Stock issued from exercise of preferred C warrants | - | - | - | - | - | - | - | - | - | - | 89,173,224 | 8,917 | (8,917) | - | - | - | - | 0 |
| Series A Preferred returned to treasury | - | (4,680) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | (4,680) |
| Sale of operating subsidiaries common | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 507,433 | 507,433 |
| Stock issued for subscribed stock | - | - | - | - | 3,110,000 | 311 | - | - | - | - | - | - | 949,689 | (190) | - | (949,810) | - | - |
| Net loss, December 31, 2023 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | (2,171,832) | (2,171,832) |
| Balance, December 31, 2023 | 60,000,000 | \$ 1,320 | 442,880,000 | \$ 44,288 | 3,452,907 | \$ 345 | - | \$ - | - | \$ - | 3,172,974,257 | \$ 317,297 | \$ 29,247,979 | 33 | \$ 12,809 | \$ 1,621,999 | \$ (34,808,508) | \$ (3,562,436) |
| See notes to financial | | | | | | | | | | | | | | | | | | |

10) Issuer Certification

Principal Executive Officer:

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, Steve G. Sharabura, certify that:

1. I have reviewed this Disclosure Statement for Enzolytics, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

April 25, 2024

/s/ Steven G. Sharabura

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

Principal Financial Officer:

I, Diana Zhabilov, certify that:

1. I have reviewed this Disclosure Statement for Enzoytics, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

April 25, 2024

/s/ Diana Zhabilov

(Digital Signatures should appear as "/s/ [OFFICER NAME]")